Talazoparib Loaded Solid Lipid Nanoparticles: Preparation, Characterization and Evaluation of the Therapeutic Efficacy In Vitro

Eskiler G. G., ÇEÇENER G., DİKMEN G., EGELİ Ü., TUNCA B.

CURRENT DRUG DELIVERY, vol.16, no.6, pp.511-529, 2019 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 16 Issue: 6
  • Publication Date: 2019
  • Doi Number: 10.2174/1567201816666190515105532
  • Journal Name: CURRENT DRUG DELIVERY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.511-529
  • Keywords: Triple Negative Breast Cancer (TNBC), PARP inhibitors, Talazoparib (BMN 673), Solid Lipid Nanoparticles (SLNs), Apoptosis, cytotoxic effects, DRUG-DELIVERY-SYSTEMS, INHIBITOR BMN 673, PARP INHIBITOR, DNA-REPAIR, MULTIDRUG-RESISTANCE, SYNTHETIC LETHALITY, HIGHLY POTENT, CANCER, CYTOTOXICITY, PACLITAXEL
  • Eskisehir Osmangazi University Affiliated: Yes

Abstract

Objective: In the present work, we report for the first time the therapeutic potential of talazoparib (BMN 673)-SLNs for the treatment of BRCA1 deficient Triple Negative Breast Cancer (TNBC). BMN 673-SLNs were produced by hot-homogenization technique and then characterized.